Nigeria, the EU and France have sealed a €10.2 million partnership under the MAV+ initiative to boost local pharmaceutical manufacturing, strengthen NIPRD’s capacity, and improve access to affordable, quality medicines.
The Federal Government, European Union (EU) and France have signed a €10.2 million agreement to strengthen Nigeria’s pharmaceutical manufacturing under the Global Gateway’s Manufacturing and Access to Vaccines, Medicines and Health Technologies (MAV+) initiative.
Implemented over 44 months (2025–2028), the Quality Uplift for Advancing Local Industry in Medicine Standards (Qualimeds Nigeria) project will expand local production of quality-assured medicines, enhance access to essential health technologies, and promote research-based innovation. It also seeks to reinforce the National Institute for Pharmaceutical Research and Development (NIPRD) as a regional reference centre for quality control and bioequivalence studies.
EU Ambassador to Nigeria, Gautier Mignot, described the partnership as “proof of the enduring collaboration between the EU, France, and Nigerian stakeholders.” France’s Ambassador, Marc Fonbaustier, said it reflects shared “values of equity, solidarity, and human dignity.”
NIPRD Director-General, Dr. Obi Adigwe, said the project would “catalyse socioeconomic development, job creation, technology transfer, and revenue generation.”